Hostname: page-component-8448b6f56d-wq2xx Total loading time: 0 Render date: 2024-04-19T21:59:27.595Z Has data issue: false hasContentIssue false
  • English
  • Français

P-504 - the Comparative Effectiveness of Second-generation Antidepressants for the Accompanying Symptoms of Depression: a Systematic Review

Published online by Cambridge University Press:  15 April 2020

K.J. Thaler ,
M. Van Noord ,
L.C. Morgan ,
B.N. Gaynes ,
L.J. Lux ,
E.E. Krebs ,
R.A. Hansen  and
G. Gartlehner
K.J. Thaler
Affiliation:
Department for Evidence-Based Medicine and Clinical Epidemiology, Danube University Krems, Krems an der Donau, Austria, USA
M. Van Noord
Affiliation:
Cecil G. Sheps Center for Health Services Research, University of North Carolina, Chapel Hill, USA
L.C. Morgan
Affiliation:
RTI International, Research Triangle Park, USA
B.N. Gaynes
Affiliation:
School of Medicine, Psychiatry, University of North Carolina, Chapel Hill, NC, USA
L.J. Lux
Affiliation:
RTI International, Research Triangle Park, USA
E.E. Krebs
Affiliation:
Roudebush VA and Regenstrief Institute, Indiana University School of Medicine, Indianapolis, IN, USA
R.A. Hansen
Affiliation:
Harrison School of Pharmacy, Department of Pharmacy Care Systems, Auburn University, Auburn, AL, USA
G. Gartlehner
Affiliation:
Department for Evidence-Based Medicine and Clinical Epidemiology, Danube University Krems, Krems an der Donau, Austria, USA RTI International, Research Triangle Park, USA

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction:

Patients with depression often suffer from accompanying symptoms that may influence the choice of second-generation antidepressant (SGA) therapy.

Objectives:

To determine the comparative effectiveness of bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, mirtazapine, nefazodone, paroxetine, sertraline, trazodone, and venlafaxine for treating common accompanying symptoms of depression.

Methods:

We searched MEDLINE®, Embase, the Cochrane Library, PsycINFO, and International Pharmaceutical Abstracts from 1980 to August 2011 and identified unpublished research. Two persons independently reviewed abstracts and full-text articles and abstracted data. We included randomized, head-to-head trials of SGAs (>6 weeks, N > 40). We graded the strength of the evidence for each symptom as high, moderate, low, or insufficient using the US Agency for Healthcare Research and Quality (AHRQ) approach.

Results:

We located 22 head-to-head trials for anxiety; insomnia; pain; melancholia; psychomotor change; or somatization. for the majority of symptoms the strength of the evidence was low or insufficient. for treating anxiety and treating depression in patients with accompanying anxiety, moderate evidence suggests there is no difference between SGAs. Likewise, for patients with depression and pain, moderate evidence suggests there is no difference between paroxetine and duloxetine for reducing the pain.

Conclusions:

Evidence guiding the selection of an SGA based on accompanying symptoms of depression is limited. Very few trials were designed and adequately powered to answer questions about accompanying symptoms; analyses were generally of subgroups in larger depression trials. Where evidence is available, it suggests no difference between SGAs in their efficacy for treating the depressive episode or the accompanying symptom.

Type
Abstract
Information
European Psychiatry , Volume 27 , Issue S1: Abstracts of the 20th European Congress of Psychiatry , 2012 , pp. 1
Copyright
Copyright © European Psychiatric Association 2012
Submit a response

Comments

No Comments have been published for this article.